TALS News and Press, Talaris Therapeutics Inc. From 10/20/22

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood di...

BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) , a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disor...

BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disor...

Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

Summary Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at ...

Talaris Therapeutics press release ( NASDAQ: TALS ): Q2 GAAP EPS of -$0.44. Talaris finished the second quarter of 2022 with $207.1M in cash, cash equivalents and marketable securities compared with $244M as of Dec. 31, 2021. For further details see: Talaris Ther...

All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection dru...

Gainers: GeoVax Labs ( GOVX ) +42% . InflaRx ( IFRX ) +37% . Sunshine Biopharma ( SBFM ) +35% . Nutriband ( NTRB ) +29% . Talaris Therapeutics ( TALS ) +24% . Chimerix ( CMRX ) +20% . Liberty TripAdvisor Holdings ...